KUALA LUMPUR (REUTERS, THE STAR/ASIA NEWS NETWORK) - Malaysia's Health Ministry said on Tuesday (Dec 14) it has given conditional approval for the use of the single-dose antibody cocktail Ronapreve, developed by Regeneron and Roche, to treat Covid-19.
It has also approved a request from Merck & Co for a clinical trial import licence for its Covid-19 pill Molnupiravir, to be used as part of studies being conducted in Malaysia, the ministry said in a statement.
"Ronapreve is indicated for the treatment of Covid-19 in adults and adolescents aged 12 years and older and weighing at least 40kg who do not require supplemental oxygen for Covid-19 and who are at increased risk of progressing to severe Covid-19," said health director-general Noor Hisham Abdullah in the statement.
He said the decision on using the drug was made at the 37th Drug Control Authority meeting on Monday.
Related Story
Regeneron's antibody drug shows protection against Covid-19 for up to 8 months
Related Story
WHO backs Regeneron Covid-19 drug cocktail as UN body calls for equal access
Join ST's Telegram channel here and get the latest breaking news delivered to you.
Topics:
More Whatsapp Linkedin FB Messenger Telegram Reddit WeChat Pinterest Print Purchase Article Copy permalink https://str.sg/3f9N